The stock has a 36-month beta value of 0.04. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for APDN is 0.51M, and at present, short sellers hold a 18.11% of that float. On June 13, 2025, the average trading volume of APDN was 125.30K shares.
APDN) stock’s latest price update
Applied Dna Sciences Inc (NASDAQ: APDN)’s stock price has soared by 9.05 in relation to previous closing price of 4.65. Nevertheless, the company has seen a loss of -7.99% in its stock price over the last five trading days. accessnewswire.com reported 2025-05-29 that STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding common stock. The Reverse Stock Split will become effective at 12:01 a.m.
APDN’s Market Performance
Applied Dna Sciences Inc (APDN) has seen a -7.99% fall in stock performance for the week, with a -57.33% decline in the past month and a -87.27% plunge in the past quarter. The volatility ratio for the week is 7.85%, and the volatility levels for the past 30 days are at 12.25% for APDN. The simple moving average for the past 20 days is -26.76% for APDN’s stock, with a -97.75% simple moving average for the past 200 days.
Analysts’ Opinion of APDN
Many brokerage firms have already submitted their reports for APDN stocks, with ROTH Capital repeating the rating for APDN by listing it as a “Buy.” The predicted price for APDN in the upcoming period, according to ROTH Capital is $24 based on the research report published on February 12, 2021 of the previous year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see APDN reach a price target of $14, previously predicting the price at $18. The rating they have provided for APDN stocks is “Buy” according to the report published on January 14th, 2021.
H.C. Wainwright gave a rating of “Buy” to APDN, setting the target price at $12 in the report published on December 18th of the previous year.
APDN Trading at -56.28% from the 50-Day Moving Average
After a stumble in the market that brought APDN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.81% of loss for the given period.
Stock Fundamentals for APDN
Current profitability levels for the company are sitting at:
- -3.44 for the present operating margin
- 0.41 for the gross margin
The net margin for Applied Dna Sciences Inc stands at -8.25. The total capital return value is set at -1.17. Equity return is now at value -141.39, with -66.28 for asset returns.
Based on Applied Dna Sciences Inc (APDN), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -28.06.
Currently, EBITDA for the company is -13.33 million with net debt to EBITDA at 0.5. When we switch over and look at the enterprise to sales, we see a ratio of -0.98. The receivables turnover for the company is 5.49for trailing twelve months and the total asset turnover is 0.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.45.
Conclusion
To sum up, Applied Dna Sciences Inc (APDN) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
